Publications
Detailed Information
Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Lee, Kewn-Wook | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Kang, Won Ki | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2021-01-31T11:11:13Z | - |
dc.date.available | 2021-01-31T11:11:13Z | - |
dc.date.created | 2018-09-12 | - |
dc.date.created | 2018-09-12 | - |
dc.date.issued | 2016-10 | - |
dc.identifier.citation | Gastric Cancer, Vol.19 No.4, pp.1095-1103 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.other | 53114 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173090 | - |
dc.description.abstract | Dacomitinib, an irreversible panHER inhibitor, shows significant preclinical antitumor activity in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC). The aim of this study was to evaluate the clinical activity of dacomitinib and discover potential biomarkers in HER2-positive GC patients. We enrolled previously treated advanced HER2-positive GC [HER2 FISH (+) or HER2 IHC 3+] patients. The patients received dacomitinib 45 mg once daily. A total of 27 patients were enrolled. The number of prior chemotherapy regimens was 1 in 7 patients (26 %), 2 in 9 patients (33 %), and more than 2 in 11 patients (41 %). Seven patients had received prior anti-HER2 therapy. The 4-month progression-free survival (PFS) rate was 22.2 % and median PFS was 2.1 months (95 % CI, 2.3-3.4) There were 2 partial response (PRs) and 9 stable disease (SDs), resulting in 7.4 % (95 % CI, 0-17.5 %) of response rate (RR) and 40.7 % (95 % CI, 21.9-59.6 %) of disease control rate (DCR). Eleven patients (41 %) showed some degree of tumor shrinkage. Overall survival was 7.1 months (95 % CI, 4.4-9.8). The most common toxicities were skin rash, diarrhea, and fatigue, most of which were grade 1 or 2. The C-trough of dacomitinib was lower in gastrectomy patients than nongastrectomy patients. Higher serum levels of HER2 extracellular domain (ECD) and lower levels of soluble E-cadherin (sECAD) correlated with higher dacomitinib activity. Dacomitinib functions as a single agent in HER2-positive GC patients with a tolerable safety profile. HER2 ECD and sECAD have the potential to be biomarkers for patient selection in a panHER inhibition strategy for HER2-positive GC. (ClinicalTrials.gov: NCT01152853). | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Phase II trial of dacomitinib in patients with HER2-positive gastric cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s10120-015-0567-z | - |
dc.citation.journaltitle | Gastric Cancer | - |
dc.identifier.wosid | 000385253600007 | - |
dc.identifier.scopusid | 2-s2.0-84947426403 | - |
dc.citation.endpage | 1103 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 1095 | - |
dc.citation.volume | 19 | - |
dc.identifier.sci | 000385253600007 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Oh, Do-Youn | - |
dc.contributor.affiliatedAuthor | Lee, Kewn-Wook | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LAPATINIB PLUS CAPECITABINE | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | SOLUBLE E-CADHERIN | - |
dc.subject.keywordPlus | PAN-HER INHIBITOR | - |
dc.subject.keywordPlus | 2ND-LINE TREATMENT | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | PF-00299804 | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | PROMOTES | - |
dc.subject.keywordAuthor | HER2 | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Dacomitinib | - |
dc.subject.keywordAuthor | HER2 ECD | - |
dc.subject.keywordAuthor | Soluble E-cadherin | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.